Jezhen's net profit surged 7 times in the third quarter... the post-COVID strategy proved effective.

The listed company SEEGEN on the KOSDAQ showed positive performance in both profitability and growth in its third-quarter results this year. Operating profit nearly doubled compared to the same period last year, and net profit surged by more than seven times.

According to the preliminary results released by SEEGEN on November 7, the consolidated benchmark operating profit for the third quarter of 2025 was 9.6 billion KRW, an increase of 82.8% compared to the same period last year. During the same period, sales reached 113.5 billion KRW, a rise of 4.3%; net profit was 14.6 billion KRW, with an increase of up to 737.4%. This improvement in performance is interpreted as the result of multiple factors, including cost structure optimization, expansion in sales of high-margin products, and recovery in demand in overseas markets.

As a professional molecular diagnostics company, SEEGEN achieved rapid rise in exports of diagnostic kits during the COVID-19 pandemic. However, due to the easing of the pandemic, the demand for diagnostics declined, and the rise once slowed down. Recently, through technological diversification and new product launch strategies, the company has gradually realized a recovery in performance. In particular, the continuous expansion of its business scope in the field of rapid diagnosis beyond cancer diagnostics and infectious diseases has laid a solid foundation for steady growth.

While the financial investment community affirms this performance, it believes that for SEEGEN to maintain its performance rise, it needs to promote a business portfolio transformation that aligns with the characteristics of the post-pandemic era. Core strategies include reducing fixed costs while simultaneously pursuing research and development investments and global market expansion.

Looking to the future, whether SEEGEN can quickly establish competitiveness in major markets such as Europe and the United States will be key to its performance trajectory. In addition, structural factors such as the global demand for infectious disease response and the growth of the regular health check market are also expected to impact the mid- to long-term stability of its performance.